Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Collegium Pharmaceutical, Inc. stands ninth among them.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a U.S.-based biopharmaceutical company specializing in innovative pain management solutions, with a focus on abuse-deterrent therapies such as BELBUCA and XTAMPZA ER. Headquartered in Stoughton, Massachusetts, the company emphasizes responsible opioid use, patient safety, and data-driven guidance for healthcare providers.

In 2025, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is showcasing its leadership in real-world evidence at PAINWeek 2025, presenting nine clinical research posters highlighting the effectiveness, safety, and clinical outcomes of its flagship products in chronic pain management. The studies provide insights into treatment patterns, safety profiles, economic impact, and opioid-use disorder outcomes, particularly in chronic low back pain patients.

By leveraging real-world data, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) aims to support clinical decision-making, reduce unnecessary exposure to high-risk opioids, and promote safer, abuse-deterrent alternatives. The business’s commitment to transparency and evidence-based guidance positions it as a leader in responsibly navigating pain management challenges and shaping clinical and policy discussions around opioid prescribing.

While we acknowledge the potential of COLL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.